Endo International | Sustainability Performance
Develops and markets branded and generic pharmaceuticals and medical devices.
1920
United States
1,001 - 5,000 employees
Pharmaceuticals
$1B - 10B in revenue
$10M - 25M in profitability
Sustainability Ranking & Industry Benchmark
#13096
Overall#2985
in United States#307
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projectionsAsset manager exclusion
Market cap
Revenue
R&D intensity
Controversy level
- Endo International plc (post-2024 Endo Inc emergence from Chapter 11) — Irish-incorporated US-operating major specialty pharmaceutical (Para Pharmaceutical/Generic, Branded Pharmaceuticals incl Vasostrict, Adrenalin) — has faced sustained scrutiny over the historic August 2022 Endo Chapter 11 bankruptcy filing (USD 8+ billion debt restructuring) following sustained US opioid litigation customer compliance affecting Endo's institutional creditor governance complexity amid US opioid sector regulatory pressure (Opana ER opioid product 2017 FDA market withdrawal).
Market cap
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$2.0BFY2023 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
5.7%FY2023
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
-158.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
3.0
▼ 1.1%
2.3
▼ 7.7%
2.0
▼ 13.5%
2.2
2024Powered by illuminem
Asset manager exclusions
Exclusions by region
Reveal data for 2 credits
Institutions excluding by region out of total tracked institutions
Excluding institutions
Reveal data for 2 credits
Institution name, type, screener label
Powered by illuminem and CovalenceEnvironmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Available
Recycling policy
Available
Workplace health & safety policy
Available
58%
Independent Directors
7 out of 12 incl. management
Overall score
52
Environment
56
Social
61
Governance
40
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
